INTRODUCTION
============

The hepatopulmonary syndrome (HPS) is characterized clinically by the triad of pulmonary vascular dilation, systemic hypoxemia and the setting of advanced liver disease^[@b1-kjim-16-2-56-2]--[@b7-kjim-16-2-56-2]^. In 1956, a case report by Rydell and Hoffbauer^[@b8-kjim-16-2-56-2]^ concerning a 17-year-old man with hypoxemia and juvenile cirrhosis provided the first clinical and postmortem documentation of what was to be later termed HPS by Knudsen and Kennedy in 1979^[@b7-kjim-16-2-56-2]^. The postmortem study demonstrated both precapillary dilations and direct arteriovenous communications after vascular injections with a plastic vinyl acetate solution^[@b9-kjim-16-2-56-2],[@b10-kjim-16-2-56-2]^.

The definition of hypoxemia may vary, but several studies consider PaO~2~ less than 70 mmHg in patients with liver disease as abnormal. An increased alveolar-arterial oxygen gradient (A-aDO~2~: greater than 20 mmHg) represents a more sensitive but less practical measure of abnormal oxygenation. Patients with HPS frequently demonstrate oxygenation that become worse as one moves from the supine to standing position (orthodoxies) breathing either room air or 100% inspired oxygen. A poor correlation exists between PaO~2~ determined while breathing room air and PaO~2~ determined while breathing 100% oxygen; the latter may be of additional prognostic significance. Research studies using a multiple inert gas elimination technique (MIGET) have shown the hypoxemia of HPS to be a result of shunt, diffusion-perfusion defect and excess perfusion for a given ventilation (low V/Q)^[@b11-kjim-16-2-56-2]^.

Most studies about hepatopulmonary syndrome have focused on alcoholic liver disease^[@b12-kjim-16-2-56-2]--[@b17-kjim-16-2-56-2]^. There is no clear data about the prevalence of HPS in postnecrotic liver cirrhosis by hepatitis B virus (HBV). And it is unclear how the presence of HPS relates to the clinical aspects of HBV induced liver cirrhosis. So this study was done to investigate the prevalence of HPS in poorly compensated postnecrotic liver cirrhosis by HBV and the correlation of HPS with clinical aspects of HBV induced poorly compensated postnecrotic liver cirrhosis.

MATERIALS AND METHODS
=====================

1.. Patients
------------

Thirty-five cirrhotic patients were randomly recruited, from both the Gastroenterology Ward and the Gastroenterology Out-patients in Seoul Municipal Boramae Hospital (Seoul National University Hospital Affiliated Hospital), Seoul, Korea. The inclusion criteria were the followings:

Liver cirrhosis was diagnosed with histological findings (85%), and with conventional clinical (positive evidence of chronic liver disease stigmata and physical findings of liver cirrhosis), ultrasonographic (coarse liver surface and shrunken liver on ultrasonography) and biochemical criteria (abnormal blood liver function test), and clinical presentations of portal hypertension (15%). All patients showed serum HBsAg positive and Child C clinical findings, with absence of cardiac or pulmonary disease and absence of pulmonary vascular abnormalities not related to liver disease.

Patients were informed about the intended procedures and the aim of the study, and consent was obtained in every case, according to the specifications guidelines of the 1975 Declaration of Helsinki. Transthoracic contrast echocardiography (TTCE) was performed in all cirrhotic patients.

2.. Transthoracic contrast echocardiography (TTCE)
--------------------------------------------------

We used a standard echocardiograph (Acuson Computerized Sonography 128XP, USA), with a 3.5 MHz transthoracic probe. Studies were recorded on videotape for further analysis. For TTCE, a previously published method[@b2-kjim-16-2-56-2] was closely followed. Four-chamber apical image was obtained through a transthoracic approach. Then, 10 mL of saline with 0.5 mL room air, were injected through the intravenous line. The second and third injection followed. A positive result was defined when microbubbles were observed in the left atrium in one or more of the three injections. The grading method was validated by examination of its reproducibility. First, the intrinsic reproducibility was examined by comparing the results obtained after the first and the second injection of each substance. Second, interobserver reproducibility was measured by assessing the concordance resulting from a two-step blind review of each register performed by the same observer. Third, interobserver reproducibility was assessed by blind comparison of the results obtained by both observers in the interpretation of each register. We did not compare two studies of the same patient performed at different times for ethical reasons.

3.. Arterial blood gas analysis (ABGA)
--------------------------------------

A sample of arterial blood was obtained in each patient at the time of the echocardiography study by puncture of the radial artery of the left arm, following the standard technique, in the supine position and breathing room air. PaO~2~ and PaCO~2~ were determined by selective electrodes (IL 16/40 ph/blood gas analyzer. Instrumentation laboratory SpA, Milano, Italy). PaO~2~ \< 70 mmHg was considered as hypoxemia. PaCO~2~ \<35 mmHg was considered as hypoxemia.

4.. Pulmonary function test
---------------------------

We used a standard pulmonary function test machine (Sensor Medic Model 2200, USA).

5.. Diagnosis of HPS
--------------------

Using saline-TTCE, we considered clinical HPS to be present in cases with PaO~2~ \< 70 mmHg with bubbles in left cardiac chambers, 'sub clinical' HPS in A-aDO~2~ greater than 20 mmHg with bubbles in left cardiac chambers.

6.. Statistical analysis
------------------------

Estimation of Kappa heavy index allowed determination of the reproducibility of the procedure and intra- and inter-observer variability. Wilcoxon's test was chosen to compare results of TTCE, and correlation between ordinal variables was determined by Spearman's test. Correlation between continuous and ordinal variables was determined by ANOVA and post-hoc test (Bonferroni). The limit of significance was set at a *p*\<0.05. For analysis purposes, we used the SPSS.

RESULTS
=======

Thirty-five patients were studied (13 women and 22 men: mean age, 53.1 ± 14.5 years) All patients were classified as Child's C. (Child's classification included assessment of total bilirubin, serum albumin, clinical ascites, nutrition and existence of encephalopathy; Child's A classification represented minimal disease and Child's C classification represented the most severe liver disease). The etiologies of liver diseases of all the patients were postnecrotic liver cirrhosis by hepative B virus.

### 1). Symptoms and signs of study population ([Table 1](#t1-kjim-16-2-56-2){ref-type="table"})

Splenomegaly and ascites were seen in all 35 patients (100%), and spider angiomas were seen in 21/35 patients (60%). Cyanosis was observed in 2 patients (6%). Esophagogastroduodenoscopy was performed before the echocardiography studies. Thirty-two patients had esophageal varies, nine of which (25.7%) were grade I, twenty of which (57.1%) were grade II, three of which (8.6%) were grade III. Japanese portal hypertension study group classification was used for esophageal varies grading ([Table 2](#t2-kjim-16-2-56-2){ref-type="table"}).

### 2). Pulmonary function test ([Table 3](#t3-kjim-16-2-56-2){ref-type="table"}) and arterial blood gas analysis ([Table 4](#t4-kjim-16-2-56-2){ref-type="table"})

Mild ventilatory defect of the restrictive type (65--79% of predicted value) was found in 7/35 patients (20%) and decrease in diffusing capacity of carbon monoxide (below 70% of predicted value) was found in 4/35 patients (11%). Significant hypoxemia (PaO~2~ \<70 mmHg) was found in 2/35 patients (5.7%) and PaO~2~ was below 80 mmHg in 4/35 patients (11%) and below 90 mmHg in 10/35 patients (29%), and the PaO~2~ value of the remaining 19/35 patients (54%) was above 90 mmHg. A-aDO~2~ were below 20 mmHg in 31/35 (88.6%) and above 20 mmHg in 4/35 patients (11.4%).

### 3). Clinical and laboratory findings of liver cirrhosis patients with positive shunt ([Table 5](#t5-kjim-16-2-56-2){ref-type="table"})

Intrapulmonary shunt was detected by TTCE in 6/35 patients (17.1%) and these cases showed significantly lower PaO~2~ than in negative intrapulmonary shunt cases (PaO~2~: 72.2 ± 15.1 vs. 90.2 ± 7.40, *p* \<0.05) and more increased A-aDO~2~ (43.1 ± 16.2 vs. 22.4 ± 7.43) than in negative intrapulmonary shunt cases.

### 4). Comparison of clinical and laboratory findings between shunt negative and positive patients ([Table 6](#t6-kjim-16-2-56-2){ref-type="table"} and [Table 7](#t7-kjim-16-2-56-2){ref-type="table"})

Except cyanosis, any clinical or laboratory findings including spider angioma, esophageal varies, biochemical indicator of hepatic function and parameters of pulmonary function test, including diffusing capacity did not distinguish between positive and negative intrapulmonary shunt patients.

DISCUSSION
==========

The triad of liver disease, arterial hypoxemia and intrapulmonary vascular dilatation has defined an entity commonly referred to as the hepatopulmonary syndrome^[@b1-kjim-16-2-56-2],[@b3-kjim-16-2-56-2],[@b10-kjim-16-2-56-2]--[@b11-kjim-16-2-56-2],[@b19-kjim-16-2-56-2],[@b26-kjim-16-2-56-2]^. In the original description by Rydell and Hoffbauer^[@b4-kjim-16-2-56-2]^, lung necropsy specimens studied using plastic vascular casts contained both precapillary/capillary dilatations and distinct anatomic arteriovenous communications which caused severe hypoxemia in the setting of chronic liver disease (juvenile cirrhosis)^[@b14-kjim-16-2-56-2],[@b16-kjim-16-2-56-2]--[@b18-kjim-16-2-56-2]^. Hepatopulmonary syndrome is becoming increasingly recognized as one of the most serious complications of chronic liver disease. Different workers have reported incidences of positive air-contrast echocardiography varying from 5 to 47%, and prevalence of HPS between 5 and 29%^[@b3-kjim-16-2-56-2],[@b14-kjim-16-2-56-2]^. Our present study, although small, suggested a relatively lower occurrence of this condition (17.1% positive intrapulmonary shunt, 5.7% hepatopulmonary syndrome) in the Korean population, among whom hepatitis B virus is the most common cause of cirrhosis (100% in the present study), compared with alcohol and hepatitis C virus in Western countries. The results from our study were similar to those from an Indian study that the prevalence of intrapulmonary shunting in hepatitis B virus induced liver cirrhosis was 8.9% but HPS with hypoxemia was only 6.7%^[@b2-kjim-16-2-56-2]^. Further studies are required to determine if the prevalence of HPS varies with etiology of liver disease or with geographical and racial differences.

Advanced hepatic dysfunction, with associated hyperdynamic circulation, has been suggested as being the most probable setting for the development of HPS. However, the condition has also been found in cases of congenital hepatic fibrosis and portal vein thrombosis. This has given rise to the question of whether portal hypertension is a contributing factor^[@b1-kjim-16-2-56-2],[@b3-kjim-16-2-56-2]^. Moreover, if hepatic dysfunction was the only prerequisite, one would expect HPS to occur predominantly among Child's class C cirrhosis. However, Abrams et al. found 15 of 25 cases of HPS (60%) had Child's grade A, and only two had grade C^[@b3-kjim-16-2-56-2]^. In this study, most of HPS cases were alcoholic liver cirrhosis and hepatitis C virus (HCV)-induced liver cirrhosis. A common bile duct legation rat model for hepatopulmonary syndrome has been developed and increased pulmonary endothelial nitric oxide syntheses activities and circulating endothelin-1 levels seem to correlate with vascular dilatation and oxygen abnormalities^[@b19-kjim-16-2-56-2],[@b26-kjim-16-2-56-2]^

In the present study, all cases were HBV-induced Child's grade C liver cirrhosis and the prevalence of HPS is 5.7%. In this small study, the prevalence of hepatopulmonay syndrome in patients with poorly compensated (Child C) postnecrotic liver cirrhosis by HBV was 5.7%. Two of 35 cases of cirrhosis (5.7%) had positive contrast echocardiography with hypoxemia (PO~2~ \<70 mmHg) and four of 35 case of cirrhosis (11.4%) were 'subclinical' cases (positive contrast echocardiography without hypoxemia). Our results suggested that "subclinical hepatopulmonary syndrome" exists and maybe there were some factors, still unknown, to determine definite hepatopulmonary syndrome (hypoxemia with positive contrast echocardiography) and subclinical hepatopulmonary syndrome. This study suggested that there was a wide clinical spectrum of hepatopulmonary syndrome. There was one report about association of esophageal varies and hepatopulmonary syndrome in liver cirrhosis^[@b27-kjim-16-2-56-2]^. But, in this study, there was no association of the grade of esophageal varies and hepatopulmonary syndrome. Cyanosis was the only reliable clinical indicator, and there was no clear relationship with the presence of spider angioma and hepatopulmonary syndrome. Further studies are required to determine if the prevalence of HPS and clinical manifestations of HPS varies with etiology or with geographical and racial differences.

###### 

Symptoms and Signs of Study Population

  Symptoms and Signs                  No. of Patients (n=35)
  ----------------------------------- ------------------------
  Resting dyspnea                     6 (17.1%)
  Platypnea                           0 (0%)
  Exertional dyspnea (ATS criteria)   
    grade I                           22 (62.9%)
    grade II                          7 (20%)
  Tachypnea                           17 (48.6%)
  Cyanosis                            2 (5.7%)
  Clubbing                            1 (2.9%)
  Ascites, splenomegaly               35 (100%)
  Spider angioma                      21 (60%)

ATS, American Thoracic Society

###### 

Laboratory Finding of Study Population

  Laboratory Findings               No. of Patients (n=35)
  --------------------------------- ------------------------
  Esophageal varies                 
    grade I                         9 (25.7%)
    grade II                        20 (57.1%)
    grade III                       3 (8.6%)
  Chest PA                          
    small amount pleural effusion   5 (14.3%)
  EKG                               
    non-significant arrhythmia      3 (8.6%)

###### 

Pulmonary Function Test Result of Study Population

  Parameter                  Degree      No. of patient (n=35)
  -------------------------- ----------- -----------------------
  FVC (% of predicted)       \>80%       28 (80.0%)
  65--80%                    7 (20.0%)   
  FEV~1~ (% of predicted)    \>80%       28 (80.0%)
  65--80%                    5 (14.3%)   
  50--64%                    2 (5.7%)    
  DLco/VA (% of predicted)   \>80%       24 (68.5%)
  65--80%                    7 (20.0%)   
  50--69%                    4 (11.4%)   

FVC, forced vital capacity

FEV~1~, forced expiratory volume in one second

DLco/VA, carbon monoxide diffusing capacity/alveolar volume

###### 

Arterial Blood Gas Analysis Result of Study Population

  Parameter                            No. of Patients (n=35)
  ------------------------------------ ------------------------
  PaO~2~ (at room air)                 
    70 mmHg \>                         2 (5.7%)
    70 mmHg ≤                          33 (94.3%)
  A-aDO~2~ (at room air)               
    20 mmHg \<                         4 (11.4%)
    20 mmHg ≥                          31 (88.6%)
  Contrast-enhanced echocardiography   
    intrapulmonary shunt               6 (17.1%)

A-aDO~2~, Alveolar-arterial oxygen difference (gradient)

###### 

Clinical Findings of Liver Cirrhosis Patients with Intrapulmonary Shunt

  Age/Sex (years)/(M/F)                                   Cyanosis   Spider angioma   Varix   FVC (%)   FEV~1~ (%)   DLco (%)   PaO~2~ (mmHg)   AaDO~2~ (mmHg)
  ------------------------------------------------------- ---------- ---------------- ------- --------- ------------ ---------- --------------- ----------------
  65/M[^\*^](#tfn6-kjim-16-2-56-2){ref-type="table-fn"}   \+         \+               −       94        96           59         57              59
  63/M[^\*^](#tfn6-kjim-16-2-56-2){ref-type="table-fn"}   \+         \+               II      117       111          66         52              68
  54/M                                                    −          −                II      106       103          101        75              32
  47/M                                                    −          −                I       77        82           70         79              32
  35/M                                                    −          −                II      82        88           73         93              33
  69/F                                                    −          −                II      91        94           74         77              34

patients with hepatopulmonary syndrome

FVC, forced vital capacity

FEV~1~, forced expiratory volume in 1 second

DLco/VA, carbon monoxide diffusion capacity/alveolar volume

A-aDO~2~, Alveolar-arterial oxygen difference

###### 

Clinical Findings Relating to Intrapulmonary Shunt

  Parameter             Shunt(−)   Shunt(+)   Significance
  --------------------- ---------- ---------- --------------
  Sex (m/f)             17:12      5:1        NS
  Smoking               16/29      3/6        NS
  Dyspnea               6/29       2/6        NS
  Dyspnea on exertion   24/29      5/6        NS
  Cyanosis              0/29       2/6        *p*\<0.05
  Clubbing              1/29       0/6        NS
  Tachypnea             13/29      4/6        NS
  Spider angioma        19/29      2/6        NS
  Esophageal varies     26/29      5/6        NS

FVC, forced vital capacity

FEV~1~, forced expiratory volume in 1 second

DLco/VA, carbon monoxide diffusion capacity/alveolar volume

A-aDO~2~, Alveolar-arterial oxygen difference

###### 

Laboratory Findings Relating to Intrapulmonary Shunt

                         Shunt (−)   Shunt (+)   Significance
  ---------------------- ----------- ----------- --------------
  Age                    52.6±15.0   55.2±12.6   NS
  Prothrombin time (%)   64.4±21.7   59.2±9.57   NS
  Albumin                2.42±0.57   2.15±0.40   NS
  Bilirubin              2.91±1.67   2.87±1.76   NS
  FVC (%)                86.3±1.47   94.5±14.9   NS
  FEV1 (%)               87.1±20.3   97.2±15.5   NS
  DLco/Va (%)            84.6±16.9   73.8±14.4   NS
  PaO~2~                 90.2±7.40   72.2±15.1   p\<0.05
  A-aDO~2~               22.4±7.43   43.1±16.2   p\<0.05
